Defence Online

Type of document: Contract Notice
Country: United Kingdom

1. Title: PHE – Corporate – Acute Drug Harms Surveillance and Early Warning System in UK Emergency Departments
2. Awarding Authority:
Public Health England
Manor Farm Road, Porton Down

Salisbury
England
SP4 0JG
Contact: Jade Palmer
Email: Jade.Palmer@phe.gov.uk
Phone: 01980619960
URL:
3. Contract Type: Services
4. Description: Public Health England (PHE) is seeking to commission an external partner with an existing system and / or capability to deliver an opioid and new psychoactive substances (NPS) clinical harms surveillance programme. The programme will:

– rapidly detect any incident involving synthetic opioids in the heroin or cocaine markets;
– monitor the emergence of a synthetic opioid market as seen in North America;
– identify health harms associated with toxicity from emerging/new NPS, such as synthetic cannabinoids.
5. CPV Codes:
75122000 – Administrative healthcare services
6. NUTS Codes: UKK15
7. Main Site or Location of Works, Main Place of Delivery or Main Place of Performance: Any region
8. Reference Attributed by the Awarding Authority:
tender_223318/810675
9. Estimated Value of Requirement: Not Provided
10. Start Date: 02/12/2019
11. End Date: 31/03/2021
12. Closing Date: 22/11/2019
13. Other Information:
Additional Text

Proposals should be emailed to jade.palmer@phe.gov.uk and include the following documentation / information:

1. supporting statement setting out and establishing suitability to undertake the project, including evidence of national/international work within the field of laboratory analysis of illicit drugs/clinical toxicology and programme management;
2. project outline with details of methodology including proposed strategy for laboratory analysis (offering the most cost-effective options most likely to ensure signals are picked up), timescales, and risks;
3. budget (including detailed breakdown of spend);
4. project team CVs.
Word count (excluding project team CVs and budget) is a max of 4,000 words.
For further information/documentation please visit: